Trial Profile
A phase I/II trial of SBI1997 patients with hepatocellular carcinoma
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 29 Dec 2015
Price :
$35
*
At a glance
- Drugs SBI 1997 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms AUDIT
- 29 Dec 2015 New trial record
- 18 Dec 2015 Saronic Biotechnology has filed an IND with the FDA, and this trial is expected to begin in Q1-Q2 2016, according to a Saronic Biotechnology media release.